Get the content you want anytime you want.
REGISTER NOW | SIGN IN

Healthcare professionals and thought leaders share their knowledge and insights on an array of infectious disease topics

Latest Videos

How Does <i>Wolbachia</i> Block Dengue Virus Transmission?
Matthew Aliota, PhD, research scientist, University of Wisconsin, Pathobiological Sciences, explains why the mechanism behind how Wolbachia blocks Dengue virus transmission is not yet fully understood.
What Are the Implications of Prolonged Zika Virus RNA Shedding?
Marta G. Cavalcanti, MD, PhD, physician at Infectious Diseases Clinic, Hospital Universitario Clementino Fraga Filho, UFRJ, Brazil, discusses how the period of RNA shedding correlates with the severity of complications associated with mono- or coinfection in Zika patients.
Evaluating CAZ-AVI Against Antibiotic-Resistant Gram-Negative Organisms
Madeline King, PharmD, assistant professor of Clinical Pharmacy at the University of the Sciences, Philadelphia College of Pharmacy in Philadelphia, Pennsylvania, discusses her research on the efficacy of ceftazidime-avibactam against infections caused by gram-negative organisms.
What Are the Social and Economic Implications of MRSA?
Edmond LaVoie, PhD, professor and chair, Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, co-founder of TAXIS Pharmaceuticals, and co-author of the study on the new MRSA drug, TXA709, discusses the social and economic implications of methicillin-resistant Staphylococcus aureus.
How Effective is TXA709 Against MRSA?
Daniel Pilch, PhD, associate professor in the Department of Pharmacology at Rutgers Robert Wood Johnson Medical School, co-founder of TAXIS Pharmaceuticals, and co-author of the study, explains why MRSA is especially dangerous, and the effectiveness of the team’s new drug, TXA079.
For Which Infections is Ceftazidime-Avibactam Approved?
Madeline King, PharmD, assistant professor of Clinical Pharmacy at the University of the Sciences, Philadelphia College of Pharmacy in Philadelphia, Pennsylvania, explains for which infections ceftazidime-avibactam is approved by the US Food and Drug Administration.
Assessing the Clinical Wellbeing of SSTI Patients
Michael D. Nailor, PharmD, BCPS-AQ ID, clinical associate professor at the University of Connecticut School of Pharmacy, clinical specialist in infectious diseases at Hartford Hospital, and director of Infectious Disease Residency program at Hartford Hospital, explains how his research can assess clinical well-being of patients with skin and soft tissue infections.
Reducing the Incidence of Acute Kidney Injury from Vancomycin & Pip/Tazo
Megan Luther, PharmD, Advanced Health Services research fellow, Providence Veterans Affairs Medical Center, University of Rhode Island, College of Pharmacy, discusses potential strategies to reduce incidence of acute kidney injuries due to vancomycin and pip/tazo combination therapy.
FEATURED
A recent study from US researchers suggests that liver disease severity and treatment costs for people with hepatitis C (HCV) vary depending on a patient's genotype.